ATRX and glioblastoma: According to EANO, combined + 7/–10 signature, EGFR amplification, and TERT promoter mutation status should be included in IDH wt diffuse astrocytic gliomas with retained nuclear ATRX expression lacking histological features of WHO grade IV (microvascular proliferation and necrosis) to allow for a diagnosis of IDH wt glioblastoma [6, 21, 25].